A 58-year-old man with type 2 diabetes mellitus and heart failure with reduced ejection fraction (HFrEF, LVEF 32%) presents for optimization of guideline-directed medical therapy. He is already on an ACE inhibitor, β-blocker, and MRA. The antidiabetic drug class marked **D** in the diagram is now initiated. Which of the following best explains why this drug class has become a cornerstone of HFrEF management, independent of its glucose-lowering effect?

Question

Accepted Answer

A. Blocks sodium-glucose cotransporter 2 in the proximal renal tubule, reducing cardiac preload through osmotic diuresis and improving HF outcomes by ~25-30% reduction in CV death/HF hospitalization. ## Why option 1 is correct

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) block sodium-glucose cotransporter 2 in the proximal renal tubule, leading to glucosuria and osmotic diuresis. This mechanism produces a modest HbA1c reduction (0.5–1%), weight loss (~2–3 kg), and BP reduction (~3–5 mmHg). Crucially, landmark trials (DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved) demonstrated that SGLT2 inhibitors reduce CV death and HF hospitalization by 25–30% in HFrEF and HFpEF *independent of diabetes status*. They are now part of the "four pillars" of guideline-directed medical therapy for HFrEF alongside ARNI, β-blockers, and MRAs (KD Tripathi 9e Ch 19; Harrison 21e Ch 405; ADA Standards 2024).

## Why each distractor is wrong

- **Option 2 (Insulin secretagogue effect)**: This describes sulfonylureas (marked **B**), not SGLT2 inhibitors. SGLT2 inhibitors do not stimulate insulin secretion and work independently of pancreatic β-cell function.
- **Option 3 (GLP-1 receptor activation)**: This describes GLP-1 agonists (marked **C**), not SGLT2 inhibitors. While GLP-1 agonists offer CV and weight-loss benefits, they do not work via SGLT2 blockade.
- **Option 4 (Hepatic glucose production inhibition)**: This is the mechanism of metformin (marked **A**). SGLT2 inhibitors work peripherally in the kidney, not by reducing hepatic gluconeogenesis.

**High-Yield:** SGLT2 inhibitors are the only antidiabetic class with proven mortality benefit in HFrEF and HFpEF *independent of diabetes status*, making them essential in modern HF management.

[cite: KD Tripathi 9e Ch 19; Harrison 21e Ch 405; ADA Standards 2024; DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved trials]

Answer

B. Stimulates insulin secretion from pancreatic β-cells, thereby improving myocardial contractility and reducing HF decompensation

Answer

C. Activates GLP-1 receptors on cardiac myocytes, promoting apoptosis of fibroblasts and reversing left ventricular remodeling

Answer

D. Inhibits hepatic glucose production, reducing circulating glucose and thereby decreasing osmotic stress on the failing myocardium

Explanation

Practice similar questions